Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stefan Englert

Showing results (21-30 of 28) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 28 results.
BMC Cancer|April 7, 2012
Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555)Nuh N Rahbari, Florian Lordick, Christine Fink, et al.
Cardiovascular Diabetology|October 11, 2014
Influence of insulin and glargine on outgrowth and number of circulating endothelial progenitor cells in type 2 diabetes patients: a partially double-blind, randomized, three-arm unicenter studyDimitrios Oikonomou, Stefan Kopf, Rüdiger von Bauer, et al.
Annals of Surgical Oncology|October 16, 2015
Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate TreatmentStefan Stefanovic, Ingo Diel, Peter Sinn, et al.
Vaccine|September 4, 2025
Adopting the estimand framework in prophylactic vaccine trialsFrancois Beckers, Naveen Karkada, Ye Yang, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 PandemicR Daniel Meyer, Bohdana Ratitch, Marcel Wolbers, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2021
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinomaAntoine Italiano, Philippe A Cassier, Chia-Chi Lin, et al.
Clinical and Translational Science|August 10, 2020
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)John Powderly, Alexander Spira, Shunsuke Kondo, et al.
Cancer Treatment and Research Communications|July 30, 2021
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancerEmiliano Calvo, Alexander Spira, María de Miguel, et al.
Pageof 3

Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
BMC Cancer|April 7, 2012
Resection of the primary tumour versus no resection prior to systemic therapy in patients with colon cancer and synchronous unresectable metastases (UICC stage IV): SYNCHRONOUS--a randomised controlled multicentre trial (ISRCTN30964555)Nuh N Rahbari, Florian Lordick, Christine Fink, et al.
Cardiovascular Diabetology|October 11, 2014
Influence of insulin and glargine on outgrowth and number of circulating endothelial progenitor cells in type 2 diabetes patients: a partially double-blind, randomized, three-arm unicenter studyDimitrios Oikonomou, Stefan Kopf, Rüdiger von Bauer, et al.
Annals of Surgical Oncology|October 16, 2015
Disseminated Tumor Cells in the Bone Marrow of Patients with Operable Primary Breast Cancer: Prognostic Impact in Immunophenotypic Subgroups and Clinical Implication for Bisphosphonate TreatmentStefan Stefanovic, Ingo Diel, Peter Sinn, et al.
Vaccine|September 4, 2025
Adopting the estimand framework in prophylactic vaccine trialsFrancois Beckers, Naveen Karkada, Ye Yang, et al.
Statistics in Biopharmaceutical Research|June 30, 2021
Statistical Issues and Recommendations for Clinical Trials Conducted During the COVID-19 PandemicR Daniel Meyer, Bohdana Ratitch, Marcel Wolbers, et al.
Cancer Immunology, Immunotherapy : CII|July 3, 2021
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinomaAntoine Italiano, Philippe A Cassier, Chia-Chi Lin, et al.
Clinical and Translational Science|August 10, 2020
Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181)John Powderly, Alexander Spira, Shunsuke Kondo, et al.
Cancer Treatment and Research Communications|July 30, 2021
Safety, pharmacokinetics, and efficacy of budigalimab with rovalpituzumab tesirine in patients with small cell lung cancerEmiliano Calvo, Alexander Spira, María de Miguel, et al.
Pageof 3